Copertina

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jing Li, Yaxin Wu, Fu‐Sheng Wang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
di: WenXian OuYang, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
di: Chen‐Pi Li, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
di: Jianrong Li, et al.
Pubblicazione: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
di: Yen‐Chun Liu, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
di: Na‐Ling Kang, et al.
Pubblicazione: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
di: Yong‐Hai Zhou, et al.
Pubblicazione: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
di: Yaomin Wang, et al.
Pubblicazione: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
di: Eiichi Ogawa
Pubblicazione: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
di: Zhuo Li, et al.
Pubblicazione: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
di: Maria Buti, et al.
Pubblicazione: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
di: Hye Won Lee, et al.
Pubblicazione: (2024)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
di: Yu Liu, et al.
Pubblicazione: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: The multifaceted role of Escherichia coli in influencing disorders of industrial populations
di: Maria Rosa Ingrosso, et al.
Pubblicazione: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
di: Lisa Sandmann, et al.
Pubblicazione: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
di: Rui Zhang, et al.
Pubblicazione: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
di: Jung Eun Park, et al.
Pubblicazione: (2024)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease
di: Jiahao Liu, et al.
Pubblicazione: (2026)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
di: Ami D. Sperber, et al.
Pubblicazione: (2024)

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma
di: Enrico N. De Toni, et al.
Pubblicazione: (2024)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
di: Haibo Jing, et al.
Pubblicazione: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data
di: John David Chetwood, et al.
Pubblicazione: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
di: Jannis Kountouras, et al.
Pubblicazione: (2024)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
di: Maryam Alahmad, et al.
Pubblicazione: (2024)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
di: Xiaosong Li, et al.
Pubblicazione: (2024)

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
di: Nipun Verma, et al.
Pubblicazione: (2024)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
di: Yan Liu, et al.
Pubblicazione: (2025)